Rapid, sensitive detection of drug resistance mutations in Mycobacterium tuberculosis is critical for guiding effective treatment. The rpoB 531 (TCG > TTG) substitution is a key marker of rifampicin resistance, and assays that can identify this single‑nucleotide change with high sensitivity and specificity are valuable for clinical diagnostics and public health. The study describes a new molecular approach that combines deliberate molecular crowding with padlock probe amplification to improve detection performance.
The authors developed an assay termed MCC‑PPA (molecular crowding conditions combined with padlock probe amplification). The core concept uses a padlock probe that is ligated when perfectly complementary to the target sequence; successful ligation produces a circular DNA template suitable for rolling‑circle amplification or related amplification steps. MCC‑PPA modifies the ligation environment by introducing crowding agents to favor probe cyclization and thereby enhance downstream amplification efficiency.
Polyethylene glycol (PEG) was employed to establish molecular crowding conditions during the padlock probe ligation step. According to the abstract, PEG enhanced padlock probe cyclization, which in turn increased amplification efficiency. The use of PEG is presented as the key modification that differentiates MCC‑PPA from conventional padlock probe amplification performed without crowding agents.
Under the conditions reported in the abstract, MCC‑PPA demonstrated a broad linear detection range spanning 10 aM to 1 nM. The lower limit of detection was reported as 4.52 aM. The total assay turnaround time was approximately 1.5 hours, indicating a rapid workflow from ligation through amplification and readout as described in the abstract.
When compared with a padlock probe amplification assay conducted in the absence of PEG (the PEG‑free condition), MCC‑PPA produced a 400‑fold enhancement in sensitivity. This quantitative improvement is attributed to the molecular crowding effect of PEG on padlock probe ligation and subsequent amplification efficiency.
The assay was evaluated on 105 clinical specimens, of which 21 carried the rpoB 531 mutation (TCG > TTG) and 84 did not. Using DNA sequencing as the reference standard, MCC‑PPA achieved 100% sensitivity and 100% specificity for identification of the rpoB 531 mutation in this cohort. These results indicate complete concordance with sequencing among the specimens included in the study sample reported in the abstract.
The authors also compared MCC‑PPA performance with fluorescence PCR melting curve analysis. For clinical detection of the rpoB 531 TCG > TTG mutation associated with rifampicin resistance, MCC‑PPA yielded 100% clinical sensitivity relative to the fluorescence PCR melting curve method, as reported in the abstract.
The combination of very low reported limit of detection, rapid assay time, and perfect concordance with sequencing in the tested clinical set suggests that MCC‑PPA may be a powerful tool for the ultrasensitive detection of single‑nucleotide resistance mutations in M. tuberculosis. The approach—enhancing padlock probe cyclization via PEG‑mediated molecular crowding—could be adaptable to other clinically relevant single‑nucleotide variants associated with antimicrobial resistance.
The abstract reports key performance metrics and the clinical concordance results but does not provide full experimental details in this summary. Specific information not reported in the abstract includes: exact PEG concentration and formulation, padlock probe sequences and design parameters, the amplification chemistry and readout modality, limits of cross‑reactivity testing, sample extraction and preparation workflow, and validation across wider or prospective clinical populations. For implementation, reproducibility assessment, and regulatory considerations, consultation of the full article is required.